AI facilitates drug development for non-small cell lung cancer, and XtalPi has reached a strategic cooperation with EDDC in Singapore

XtalPi has partnered with Singapore's National Drug Development Platform to develop more effective and precise treatment options for lung cancer patients worldwide

SHENZHEN & SINGAPORE, Dec.
20, 2022 /PRNewswire/ -- XtalPi and Singapore's National Drug Development Platform, the Center for Experimental Drug Discovery (EDDC), have reached a strategic collaboration to drive drug discovery with artificial intelligence (AI), automated experiments, and expert experience for non-small cell lung cancer (NSCLC) targets selected by EDDC.
Offering new drug
candidates for the precision treatment of lung cancer.
As Singapore's national drug development platform, EDDC is managed by the Agency for Science, Technology and Research (A*STAR) and aims to strengthen Singapore's R&D capabilities in the biomedical sector and promote R&D translation
.

Lung cancer is the second most common cancer worldwide and the leading cause of
cancer death.
According to the statistics of the international academic journal "Annals of Oncology", non-small cell lung cancer accounts for more than 80% of all lung cancer cases, and the incidence rate continues to increase
worldwide.
Research and Markets, an international market research firm, estimates that the global market for non-small cell lung cancer therapies will exceed $20 billion
by 2027.
Compared with the increasing number of new drug research and investment scale, there is still a large unmet clinical need
for more effective targeted therapy regimens for patients with non-small cell lung cancer.

In this new drug development project for non-small cell lung cancer, XtalPi will use its self-developed "intelligent automated drug discovery system" to generate and screen millions of molecules in the drug design stage, predict the most potential drug molecules, and quickly iteratively optimize through automated laboratory verification, and finally obtain more ideal preclinical candidate compounds (PCCs
).
EDDC will provide valuable insights and research data on novel non-small cell lung cancer targets, further accelerating the drug discovery process and driving the project to milestones
.

Dr.
Shuhao Wen, Co-Founder and Chairman of XtalPi, said, "We are honored to have a strategic partnership
with EDDC.
XtalPi is committed to serving patients worldwide by increasing the speed, scale, novelty, and success rate of drug discovery through cutting-edge technologies such as artificial intelligence and automation
.
Through this collaboration, we hope to continue to expand and strengthen cooperation with top scientific research institutions around the world, and jointly accelerate drug development innovation and achievement transformation under the guidance of clinical needs, so as to contribute to
prolonging the lives of patients and improving their quality of life.
" ”

Professor Damian O'Connell, CEO of EDDC, said, "We are excited to partner with XtalPi to translate science and research into effective targeted therapies to treat cancer
.
With XtalPi's expertise in AI and automation technologies, we believe this collaboration will accelerate the development of much-needed targeted therapies
for NSCLC patients.
" ”